Advancing opportunities in real-world data and real-world evidence is critical to address the evolving health needs created by the COVID-19 pandemic. To further that work, the FDA Foundation is pleased to embark on an exciting program to evaluate the Real-World Performance of In Vitro Diagnostics (PIVD). 

In June of 2021, the Therapeutics Parallel Analysis (TxPA) work group of the COVID-19 Evidence Accelerator paused to conduct a retrospective or “retro”. For those of you who are unfamiliar with the expression, a retro is an opportunity to review the work of a previous cycle or “sprint” in Agile terminology. A retro allows the Evidence Accelerator community the opportunity to step back and see how far we have come, what went well, and where we could make improvements.